Generics A recent Intellectual Property Appellate Board (IPAB) order has resulted in the generic version of anti-cancer drug Ibrutinib becoming illegal once again, leaving patients with no option but to go back to buying Ibrutinib, sold under the brand name Imbruvica at $5,283. The revoked patent has granted a fresh lease of life to the on-going litigation between Big pharma and domestic drug companies, reports The Pharma Letter’s India correspondent. 25 June 2020